Antifibrinolytic Drugs Market - Forecasts from 2020 to 2025
Global anti-fibrinolytic drug market was valued at US$21.134 billion in 2019. Antifibrinolytics are used to slow down the process of breaking down a blood clot. These drugs are majorly used to treat heavy menstrual bleeding and hemorrhages. Antifibrinolytic drugs are necessary to avert clot degradation in fibrinolysis prone areas such as a nasal cavity, oral cavity, and female reproductive tract.
The rise in the number of surgeries around the globe is the major driver of the global anti-fibrinolytic drug market. These drugs are used in various surgeries including cardiovascular and dental surgeries. Another factor that is fueling the market growth of the global anti-fibrinolytic drug is the increasing number of road accidents. According to the World Health Organization (WHO), approximately 1.35 million people die annually as a result of road traffic accidents. Also, road traffic injuries are the leading cause of death among children and young adults aged between 5 and 29 years. Since these drugs avert clot lysis and reduce blood loss, their demand is augmenting with an increasing number of road accidents and injuries, thus spurring the overall market growth.
The growing global geriatric population is also a major driver of the anti-fibrinolytic drug market. According to the United Nations statistics, the number of people aged 60 years or above is projected to rise from 962.3 million in 2017 to 2080.5 million by 2050. The rising aging population is boosting the demand for these drugs as the demographic shift towards an older population is putting a higher burden on various age-associated diseases worldwide. Factors such as increased life expectancy and declining fertility are the key factors behind the growing aging population across the globe. Since it is difficult to keep the blood clot in case of surgery or any injury among this population group, the demand for anti-fibrinolytic drugs is escalating with the increasing number of older people worldwide.
Furthermore, these drugs are increasingly used by women to control heavy menstrual flow which is also a prominent factor behind the growth of the global anti-fibrinolytic drug market. The growing prevalence of angioedema will continue to spur the global anti-fibrinolytic drug market growth during the forecast period. The availability of the anti-fibrinolytic drug in both oral and injection forms also contributes to the market growth of anti-fibrinolytic drugs to some extent. In July 2017, Zydus Cadila received the final approval from the U.S. Food and Drug Administration (FDA) to market Tranexamic Acid Injection, 1000mg/10mL Single-dose vial. This medication is used to prevent or reduce bleeding in patients with hemophilia who require tooth extraction.
The global anti-fibrinolytic drug market is segmented by indication, route of administration, end-user, and geography. On the basis of indication, the global anti-fibrinolytic drug market is segmented as surgeries (cardiac, dental, and others), menorrhagia, and hereditary angioedema (HAE). By route of administration, the global anti-fibrinolytic drug market segmentation is done as oral and injection. By end-user, the global anti-fibrinolytic drug market is segmented as hospital and clinics, and ambulatory surgical centers.
Increasing demand for anti-fibrinolytic drugs among women to treat menorrhagia
The prescribed anti-fibrinolytic drug market holds a noteworthy market share throughout the forecast period. The heavy menstrual bleeding segment accounted for the significant market share in 2019 and is poised to witness a prominent growth rate during the forecast period. A rise in the prevalence of menorrhagia among women leading them to visit gynecologists in order to get prescribed anti-fibrinolytic drugs, thereby spurring the overall market growth. Tranexamic acid (TXA) is the most widely used anti-fibrinolytic drug for this purpose. Increasing number of cardiac and brain surgeries will lead to the growth of the surgeries segment during the forecast period.
Hospitals and Clinics hold the larger market share
By end-user, hospitals and clinics segment dominates the global anti-fibrinolytic drug market as most of the surgeries take place in hospitals. With the increasing number of surgeries worldwide, the increased demand for these drugs in hospitals bolsters the global anti-fibrinolytic drug market growth during the forecast period.
By geography, North America holds a significant market share
Regionally, the global anti-fibrinolytic drug market is classified into North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America accounted for a significant share in the global anti-fibrinolytic drug market in 2019. The presence of major pharmaceutical companies in the region contributes significantly to the notable share of this region in the global anti-fibrinolytic drug market. The growing adoption of anti-fibrinolytic drugs to control menstrual flow is significantly contributing to the market growth of anti-fibrinolytic drugs in this region. Moreover, a continuous rise in the number of surgeries in countries like the U.S., Canada, and Mexico is further augmenting the demand for anti-fibrinolytic drugs, thus positively impacting the regional market growth. According to the OECD (Organization for Economic Cooperation and Development) data, the number of surgeries increased from 1,100,675 in 2011 to 1,182,649 in 2018. Similarly, in Mexico, the total number of surgeries surged from 6,57,730 in 2011 to 8,35,606 in 2018. Asia Pacific (APAC) is projected to witness a substantial compound annual growth rate during the forecast period due to a surge in the number of road traffic injuries and accidents. For example, in November 2019, according to the report by the Indian Ministry of Road Transport and Highways, the country witnessed a rise of 0.46 percent in total road accidents in 2018 as compared to 2017. The rising focus among women regarding their health is also leading to the demand for anti-fibrinolytic drugs to control heavy menstrual flow, thus propelling the anti-fibrinolytic drug market growth in this region.
Market Players and Competitive Intelligence
Prominent key market players in the global anti-fibrinolytic drug market include GenMed, a division of Pfizer Canada Inc., Zydus Cadila, Mylan N.V., Xanodyne Pharmaceuticals, Inc., and American Regent, Inc. among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in the global anti-fibrinolytic drug market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.
Segmentation
The rise in the number of surgeries around the globe is the major driver of the global anti-fibrinolytic drug market. These drugs are used in various surgeries including cardiovascular and dental surgeries. Another factor that is fueling the market growth of the global anti-fibrinolytic drug is the increasing number of road accidents. According to the World Health Organization (WHO), approximately 1.35 million people die annually as a result of road traffic accidents. Also, road traffic injuries are the leading cause of death among children and young adults aged between 5 and 29 years. Since these drugs avert clot lysis and reduce blood loss, their demand is augmenting with an increasing number of road accidents and injuries, thus spurring the overall market growth.
The growing global geriatric population is also a major driver of the anti-fibrinolytic drug market. According to the United Nations statistics, the number of people aged 60 years or above is projected to rise from 962.3 million in 2017 to 2080.5 million by 2050. The rising aging population is boosting the demand for these drugs as the demographic shift towards an older population is putting a higher burden on various age-associated diseases worldwide. Factors such as increased life expectancy and declining fertility are the key factors behind the growing aging population across the globe. Since it is difficult to keep the blood clot in case of surgery or any injury among this population group, the demand for anti-fibrinolytic drugs is escalating with the increasing number of older people worldwide.
Furthermore, these drugs are increasingly used by women to control heavy menstrual flow which is also a prominent factor behind the growth of the global anti-fibrinolytic drug market. The growing prevalence of angioedema will continue to spur the global anti-fibrinolytic drug market growth during the forecast period. The availability of the anti-fibrinolytic drug in both oral and injection forms also contributes to the market growth of anti-fibrinolytic drugs to some extent. In July 2017, Zydus Cadila received the final approval from the U.S. Food and Drug Administration (FDA) to market Tranexamic Acid Injection, 1000mg/10mL Single-dose vial. This medication is used to prevent or reduce bleeding in patients with hemophilia who require tooth extraction.
The global anti-fibrinolytic drug market is segmented by indication, route of administration, end-user, and geography. On the basis of indication, the global anti-fibrinolytic drug market is segmented as surgeries (cardiac, dental, and others), menorrhagia, and hereditary angioedema (HAE). By route of administration, the global anti-fibrinolytic drug market segmentation is done as oral and injection. By end-user, the global anti-fibrinolytic drug market is segmented as hospital and clinics, and ambulatory surgical centers.
Increasing demand for anti-fibrinolytic drugs among women to treat menorrhagia
The prescribed anti-fibrinolytic drug market holds a noteworthy market share throughout the forecast period. The heavy menstrual bleeding segment accounted for the significant market share in 2019 and is poised to witness a prominent growth rate during the forecast period. A rise in the prevalence of menorrhagia among women leading them to visit gynecologists in order to get prescribed anti-fibrinolytic drugs, thereby spurring the overall market growth. Tranexamic acid (TXA) is the most widely used anti-fibrinolytic drug for this purpose. Increasing number of cardiac and brain surgeries will lead to the growth of the surgeries segment during the forecast period.
Hospitals and Clinics hold the larger market share
By end-user, hospitals and clinics segment dominates the global anti-fibrinolytic drug market as most of the surgeries take place in hospitals. With the increasing number of surgeries worldwide, the increased demand for these drugs in hospitals bolsters the global anti-fibrinolytic drug market growth during the forecast period.
By geography, North America holds a significant market share
Regionally, the global anti-fibrinolytic drug market is classified into North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America accounted for a significant share in the global anti-fibrinolytic drug market in 2019. The presence of major pharmaceutical companies in the region contributes significantly to the notable share of this region in the global anti-fibrinolytic drug market. The growing adoption of anti-fibrinolytic drugs to control menstrual flow is significantly contributing to the market growth of anti-fibrinolytic drugs in this region. Moreover, a continuous rise in the number of surgeries in countries like the U.S., Canada, and Mexico is further augmenting the demand for anti-fibrinolytic drugs, thus positively impacting the regional market growth. According to the OECD (Organization for Economic Cooperation and Development) data, the number of surgeries increased from 1,100,675 in 2011 to 1,182,649 in 2018. Similarly, in Mexico, the total number of surgeries surged from 6,57,730 in 2011 to 8,35,606 in 2018. Asia Pacific (APAC) is projected to witness a substantial compound annual growth rate during the forecast period due to a surge in the number of road traffic injuries and accidents. For example, in November 2019, according to the report by the Indian Ministry of Road Transport and Highways, the country witnessed a rise of 0.46 percent in total road accidents in 2018 as compared to 2017. The rising focus among women regarding their health is also leading to the demand for anti-fibrinolytic drugs to control heavy menstrual flow, thus propelling the anti-fibrinolytic drug market growth in this region.
Market Players and Competitive Intelligence
Prominent key market players in the global anti-fibrinolytic drug market include GenMed, a division of Pfizer Canada Inc., Zydus Cadila, Mylan N.V., Xanodyne Pharmaceuticals, Inc., and American Regent, Inc. among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in the global anti-fibrinolytic drug market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.
Segmentation
- By Indication
- Surgeries
- Cardiac
- Dental
- Others
- Menorrhagia
- Hereditary Angioedema (HAE)
- By Route of Administration
- Oral
- Injection
- By End User
- Hospital and Clinics
- Ambulatory Surgical Centers
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- United Kingdom
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- UAE
- Others
- Asia Pacific
- China
- Japan
- South Korea
- India
- Others
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Product Pipeline
4.5. Industry Value Chain Analysis
5. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY INDICATION
5.1. Introduction
5.2. Surgeries
5.2.1. Cardiac
5.2.2. Dental
5.2.3. Others
5.3. Menorrhagia
5.4. Hereditary Angioedema (HAE)
6. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION
6.1. Introduction
6.2. Oral
6.3. Injection
7. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY END USER
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Ambulatory Surgical Centers
8. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. North America Anti-Fibrinolytic Drug Market, By Indication
8.2.2. North America Anti-Fibrinolytic Drug Market, By Route of Administration
8.2.3. North America Anti-Fibrinolytic Drug Market, By End User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. South America Anti-fibrinolytic Drug Market, By Indication
8.3.2. South America Anti-fibrinolytic Drug Market, By Route of Administration
8.3.3. South America Anti-fibrinolytic Drug Market, By End User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. Europe Anti-fibrinolytic Drug Market, By Indication
8.4.2. Europe Anti-fibrinolytic Drug Market, By Route of Administration
8.4.3. Europe Anti-fibrinolytic Drug Market, By End User
8.4.4. By Country
8.4.4.1. Germany
8.4.4.2. France
8.4.4.3. United Kingdom
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. Middle East and Africa Anti-Fibrinolytic Drug Market, By Indication
8.5.2. Middle East and Africa Anti-Fibrinolytic Drug Market, By Route of Administration
8.5.3. Middle East and Africa Anti-Fibrinolytic Drug Market, By End User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. Israel
8.5.4.3. UAE
8.5.4.4. Others
8.6. Asia Pacific
8.6.1. Asia Pacific Anti-fibrinolytic Drug Market, By Indication
8.6.2. Asia Pacific Anti-fibrinolytic Drug Market, By Route of Administration
8.6.3. Asia Pacific Anti-fibrinolytic Drug Market, By End User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. South Korea
8.6.4.4. India
8.6.4.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. GenMed, a division of Pfizer Canada Inc.
10.2. Zydus Cadila
10.3. Mylan N.V.
10.4. Xanodyne Pharmaceuticals, Inc.
10.5. American Regent, Inc.
*list is not exhaustive
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Product Pipeline
4.5. Industry Value Chain Analysis
5. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY INDICATION
5.1. Introduction
5.2. Surgeries
5.2.1. Cardiac
5.2.2. Dental
5.2.3. Others
5.3. Menorrhagia
5.4. Hereditary Angioedema (HAE)
6. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION
6.1. Introduction
6.2. Oral
6.3. Injection
7. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY END USER
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Ambulatory Surgical Centers
8. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. North America Anti-Fibrinolytic Drug Market, By Indication
8.2.2. North America Anti-Fibrinolytic Drug Market, By Route of Administration
8.2.3. North America Anti-Fibrinolytic Drug Market, By End User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. South America Anti-fibrinolytic Drug Market, By Indication
8.3.2. South America Anti-fibrinolytic Drug Market, By Route of Administration
8.3.3. South America Anti-fibrinolytic Drug Market, By End User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. Europe Anti-fibrinolytic Drug Market, By Indication
8.4.2. Europe Anti-fibrinolytic Drug Market, By Route of Administration
8.4.3. Europe Anti-fibrinolytic Drug Market, By End User
8.4.4. By Country
8.4.4.1. Germany
8.4.4.2. France
8.4.4.3. United Kingdom
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. Middle East and Africa Anti-Fibrinolytic Drug Market, By Indication
8.5.2. Middle East and Africa Anti-Fibrinolytic Drug Market, By Route of Administration
8.5.3. Middle East and Africa Anti-Fibrinolytic Drug Market, By End User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. Israel
8.5.4.3. UAE
8.5.4.4. Others
8.6. Asia Pacific
8.6.1. Asia Pacific Anti-fibrinolytic Drug Market, By Indication
8.6.2. Asia Pacific Anti-fibrinolytic Drug Market, By Route of Administration
8.6.3. Asia Pacific Anti-fibrinolytic Drug Market, By End User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. South Korea
8.6.4.4. India
8.6.4.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. GenMed, a division of Pfizer Canada Inc.
10.2. Zydus Cadila
10.3. Mylan N.V.
10.4. Xanodyne Pharmaceuticals, Inc.
10.5. American Regent, Inc.
*list is not exhaustive
